Neuren Pharmaceuticals achieves breakthrough in Pitt Hopkins syndrome treatment

Pallavi Madhiraju- May 28, 2024 0

Neuren Pharmaceuticals (ASX: NEU) has announced promising top-line results from its Phase 2 clinical trial of NNZ-2591, aimed at treating children with Pitt Hopkins syndrome ... Read More

Rezolute’s Phase 2 trial of RZ402 shows significant CST reduction in DME patients

Pallavi Madhiraju- May 22, 2024 0

Rezolute, Inc. (Nasdaq: RZLT), a leader in the development of novel therapies for serious metabolic and rare diseases, today disclosed promising topline results from its ... Read More

EyePoint Pharmaceuticals reports mixed results for DURAVYU in Phase 2 diabetic retinopathy trial

Pallavi Madhiraju- May 7, 2024 0

EyePoint Pharmaceuticals, Inc., committed to innovative therapeutics for serious retinal diseases, today disclosed the top-line results of the Phase 2 PAVIA clinical trial for DURAVYU ... Read More